Organization (Hospital)
CHU de Québec-Université Laval
ClinicalTrials.gov lists CHU de Québec-Université Laval as lead sponsor of 137 trials. It has 51 active development programs and 32 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 9 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 11 in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers CHU de Québec-Université Laval: 137 lead-sponsored trials and 1 legal-entity registration.
Disease areas (154)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Prostatic Neoplasms | 16 |
| Diabetes Mellitus | 11 |
| Pain | 11 |
| Premature Birth | 9 |
| Breast Neoplasms | 7 |
Showing 5 of 154 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 9 |
| 2025 | 6 |
| 2024 | 7 |
| 2023 | 9 |
| 2022 | 10 |
| 2021 | 11 |
| 2020 | 8 |
| 2019 | 12 |
| 2018 | 14 |
| 2017 | 12 |
Showing 10 of 26 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; 12 of 13 predicted trials reach the 36-month horizon; registered median of 35 months across 89 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (51)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| pr Sandoz Tamsulosin | Urinary Retention | Phase 3 | 1 |
| Anhydrous glucose | Urinary Retention | Phase 3 | 1 |
| 177Lu-Octreotate | Carcinoma, Neuroendocrine | Phase 2 | 1 |
| Enzalutamide Capsule | Prostatic Neoplasms | Phase 2 | 1 |
| 177Lu-Octreotate | Carcinoid Tumor | Phase 2 | 1 |
Showing 5 of 51 active programs.
Approved assets (32)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| TasP using ART regimen as per Benin guidelines | 1 |
| Acetylsalicylic Acid 160 mg | 1 |
| Acetylsalicylic Acid 80 mg | 1 |
| Target trough IgG level 4-6 g/L | 1 |
| Generic latanoprost | 1 |
Showing 5 of 32 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 45% hit target (n=31) | 25% on time (n=40) |
Journals published in (282)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of clinical endocrinology and metabolism | 19 |
| BMJ open | 17 |
| The Cochrane database of systematic reviews | 12 |
| The Journal of trauma | 12 |
| International journal of radiation oncology, biology, physics | 11 |
Showing 5 of 282 journals.
Organization relationships (44)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| St. Justine's Hospital | Co sponsors trial with | 5 |
| The Hospital for Sick Children | Co sponsors trial with | 3 |
| Montreal Children's Hospital of the MUHC | Co sponsors trial with | 2 |
| Canadian Traumatic Brain Injury Research Consortium | Co sponsors trial with | 2 |
| The Arthritis Society, Canada | Co sponsors trial with | 2 |
Showing 5 of 44 relationships.
Latest dated events (187)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 187 events.
Biomarker capability evidence (118)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial collaborator | Named in trial inclusion criteria |
| AGT | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| APOE | Trial collaborator | Named in trial inclusion criteria |
| ARIH1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 118 evidence rows.
Biomarkers this organization publishes on (115)
Shown in this order: most publications first.
Showing 5 of 115 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.